Diabetic eye disease poses a significant threat to visual acuity in a large portion of our patients, and the past year has been extremely encouraging with the recent approval of intravitreal anti-vascular endothelial growth factor therapy for diabetic retinopathy, representing an opportunity for a medical approach to treating the condition, and a major trial providing guidance on the management of patients with diabetic macular edema. Careful interpretation of the changing landscape in the management of diabetic eye disease is critical to ensure the best visual outcomes for our patients.
We invite you to participate in the special half-day continuing medical education program, “Retina Forum® 2016—Diabetic Retinopathy: A Revolution in Treatment Options,” which will offer a state-of-the-science look at how we should be managing our patients with diabetic macular edema and proliferative diabetic retinopathy.
The course is specifically directed to experienced retina specialists. We have recruited a nationally recognized faculty to present the latest clinical data and to discuss their approaches to treating patients with diabetic eye disease.
The course will be fast-paced and interactive, with case presentations intended to foster audience participation.
We hope you can join us for this program.
With best regards,
2016 Program Planning Committee
Andrew A. Moshfeghi, MD, MBA
Rishi P. Singh, MD